Scholarlink

Abstract <p>The purpose of this study was to investigate the efficacy and safety of add-on metformin treatment in persons with active epilepsy (a-PWE). This is a single-centric, double-blind, placebo-controlled trial randomised a-PWE (1:1) to receive either metformin (extended-release 500&#xa0;mg) or matching placebo for 6&#xa0;months along with background antiseizure medications. Primary outcome was percentage change in seizure frequency/month, and secondary outcomes were 50% responder rate, serum mTOR expression, and serum total antioxidant capacity (TAC), body composition analysis, quality of life (QOL), and safety assessment. Among the randomised a-PWE (<i>n</i> = 60, 30 in each group), no significant difference in percentage change in seizure frequency/month [median (IQR), 5.00 (− 11.25 to 23.45) vs. 0 (− 15.00 to 25.00), median difference (95% CI), 0 (− 18.75 to 12.50), <i>p</i> = 0.687], mTOR expression, TAC, and QOL was noted between metformin and placebo. Compared to baseline, QOL was significantly improved (<i>p</i> = 0.019) in metformin group, but this was not evident in placebo. Body composition analysis revealed a significant increase in percentage-change in BMI (<i>p</i> &lt; 0.001), fat % (<i>p</i> = 0.011), and fat mass (<i>p</i> = 0.004) in placebo compared to metformin. No significant safety concern was observed in metformin group, rather Liverpool adverse event profile (LAEP) score was significantly lower than placebo (<i>p</i> = 0.014). Significant improvement in lipid profile (triglycerides and high-density lipoprotein) and glycaemic parameters was observed in metformin group compared to baseline. Metformin intervention at the selected dose was not effective in terms of seizure reduction or modulation of mTOR expression compared to placebo. Further studies with higher dose with longer duration of intervention may be needed to establish the findings.&#xa0;Trial registration no.&#xa0;CTRI/2023/10/058825, date: 18.10.2023.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adjuvant potential of metformin with standard anti-seizure medications in persons with active epilepsy: a randomised controlled trial

  • 期刊论文

  • 发表日期：

    2025年9月10日

查看全文
  • Sudhir Chandra Sarangi,
  • Soumya Sucharita Pattnaik,
  • Ratnav Singh,
  • Yajnaseni Dash,
  • Manjari Tripathi,
  • Surender Singh,
  • Maroof Ahmad Khan

摘要

Abstract

The purpose of this study was to investigate the efficacy and safety of add-on metformin treatment in persons with active epilepsy (a-PWE). This is a single-centric, double-blind, placebo-controlled trial randomised a-PWE (1:1) to receive either metformin (extended-release 500 mg) or matching placebo for 6 months along with background antiseizure medications. Primary outcome was percentage change in seizure frequency/month, and secondary outcomes were 50% responder rate, serum mTOR expression, and serum total antioxidant capacity (TAC), body composition analysis, quality of life (QOL), and safety assessment. Among the randomised a-PWE (n = 60, 30 in each group), no significant difference in percentage change in seizure frequency/month [median (IQR), 5.00 (− 11.25 to 23.45) vs. 0 (− 15.00 to 25.00), median difference (95% CI), 0 (− 18.75 to 12.50), p = 0.687], mTOR expression, TAC, and QOL was noted between metformin and placebo. Compared to baseline, QOL was significantly improved (p = 0.019) in metformin group, but this was not evident in placebo. Body composition analysis revealed a significant increase in percentage-change in BMI (p < 0.001), fat % (p = 0.011), and fat mass (p = 0.004) in placebo compared to metformin. No significant safety concern was observed in metformin group, rather Liverpool adverse event profile (LAEP) score was significantly lower than placebo (p = 0.014). Significant improvement in lipid profile (triglycerides and high-density lipoprotein) and glycaemic parameters was observed in metformin group compared to baseline. Metformin intervention at the selected dose was not effective in terms of seizure reduction or modulation of mTOR expression compared to placebo. Further studies with higher dose with longer duration of intervention may be needed to establish the findings. Trial registration no. CTRI/2023/10/058825, date: 18.10.2023.